Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.

Tipping AJ, Baluch S, Barnes DJ, Veach DR, Clarkson BM, Bornmann WG, Mahon FX, Goldman JM, Melo JV.

Leukemia. 2004 Aug;18(8):1352-6.

PMID:
15201856
2.

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.

Manley PW, Cowan-Jacob SW, Mestan J.

Biochim Biophys Acta. 2005 Dec 30;1754(1-2):3-13. Review.

PMID:
16172030
3.

Important therapeutic targets in chronic myelogenous leukemia.

Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.

Clin Cancer Res. 2007 Feb 15;13(4):1089-97. Review.

4.

Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.

Quintás-Cardama A, Kantarjian H, Cortes J.

Future Oncol. 2006 Dec;2(6):655-65. Review.

PMID:
17155893
5.

New strategies in controlling drug resistance.

Frame D.

J Manag Care Pharm. 2007 Oct;13(8 Suppl A):13-7. Review.

6.

Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.

Giles FJ, Cortes JE, Kantarjian HM.

Curr Mol Med. 2005 Nov;5(7):615-23. Review.

PMID:
16305488
7.

Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.

Melo JV, Chuah C.

Hematology Am Soc Hematol Educ Program. 2008:427-35. doi: 10.1182/asheducation-2008.1.427. Review.

PMID:
19074121
8.

Targeted drugs in chronic myeloid leukemia.

Gora-Tybor J, Robak T.

Curr Med Chem. 2008;15(29):3036-51. Review.

PMID:
19075651
9.

Dual tyrosine kinase inhibitors in chronic myeloid leukemia.

Martinelli G, Soverini S, Rosti G, Baccarani M.

Leukemia. 2005 Nov;19(11):1872-9. Review.

PMID:
16179913
10.

Therapy options in imatinib failures.

Ramirez P, DiPersio JF.

Oncologist. 2008 Apr;13(4):424-34. doi: 10.1634/theoncologist.2007-0170. Review.

11.

Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias.

Nimmanapalli R, Bhalla K.

Curr Opin Oncol. 2002 Nov;14(6):616-20. Review.

PMID:
12409651
12.

Targeted chronic myeloid leukemia therapy: seeking a cure.

Fausel C.

J Manag Care Pharm. 2007 Oct;13(8 Suppl A):8-12. Review.

13.
14.

[Preclinical and clinical profile of imatinib mesilate, a potent protein-tyrosine kinase inhibitor for CML therapy].

Toga W, Kondo M, Tokoro A.

Nihon Yakurigaku Zasshi. 2003 Feb;121(2):119-28. Review. Japanese.

PMID:
12616857
15.

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.

Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J.

Ann Intern Med. 2006 Dec 19;145(12):913-23. Review.

PMID:
17179059
16.

[Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].

Grzybowska-Izydorczyk O, Góra-Tybor J, Robak T.

Postepy Hig Med Dosw (Online). 2006;60:490-7. Review. Polish.

17.

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).

Walz C, Sattler M.

Crit Rev Oncol Hematol. 2006 Feb;57(2):145-64. Review.

PMID:
16213151
18.

[STI571: a summary of targeted therapy].

Czyz M, Jakubowska J.

Postepy Hig Med Dosw (Online). 2006;60:677-96. Review. Polish.

19.

Molecular and cellular bases of chronic myeloid leukemia.

Chen Y, Peng C, Li D, Li S.

Protein Cell. 2010 Feb;1(2):124-32. doi: 10.1007/s13238-010-0016-z. Review.

20.

Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.

Bixby D, Talpaz M.

Hematology Am Soc Hematol Educ Program. 2009:461-76. doi: 10.1182/asheducation-2009.1.461. Review.

PMID:
20008232

Supplemental Content

Support Center